Lupin News and Updates

Name: Latest research reports of Lupin Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news on Lupin from all sources in a single place.

Lupin Ltd.

02 Dec 2025

2054.80

-0.77%

Lupin hits seven-month high as US portfolio and margins drive gains

Business Standard

Lupin's stock rose after a strong Q2FY26 led by the US business and a sharp jump in margins. Analysts see Tolvaptan exclusivity and complex generics supporting earnings momentum

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin Ltd.

01 Dec 2025

2054.80

-0.77%

Lupin Gets USFDA Nod For Biosimilar Drug

NDTV Profit

Armlupeg is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

Lupin Ltd. is trading above all available SMAs

Lupin gets USFDA nod for biosimilar drug

Business Line | 01 Dec 2025 1 more

Lupin Ltd.

25 Nov 2025

2054.80

-0.77%

LUPIN LIMITED

Buy: Lupin Ltd.

Recommendation Target

Geojit BNP Paribas

In Q2FY26, Lupin reported a consolidated revenue of Rs. 7,048cr, up 24.2% YoY, Lupin's India segment revenue rose 3.4% YoY to Rs. 2,078cr, led by an 8.8% growth in Rx business, strong chronic therapy momentum and robust volume growth,...

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.

Lupin Ltd.

20 Nov 2025

2054.80

-0.77%

Lupin, Fortis Among Axis Securities Top 'Buy' In Pharma, Healthcare Space; Q2 Review Details Inside

NDTV Profit

The healthcare space continues to outperform and pharma sector impacted by US generics in Q2, adds the brokerage.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

13 Nov 2025

2054.80

-0.77%

Record quarter with broad-based growth, strong U.S. momentum, and sharp margin expansion

Buy: Lupin Ltd.

Deven Choksey

Lupin remains well-positioned to sustain its strong growth trajectory, supported by a healthy specialty pipeline in the U.S., improved product mix, and operating leverage gains.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

11 Nov 2025

2054.80

-0.77%

Lupin Ltd

Buy: Lupin Ltd.

Recommendation Target

ICICI Direct

Niche launches in the US drive numbers; future pipeline key for sustainability Earning momentum strong till FY26; apparent slowdown in FY27 but pipeline buildup to continue- Strong growth was attributable US launches under exclusivity (gMyrbetriq, gTolvaptan and gSpiriva) and launches across regions. India was impacted due to lower tender sales in Institutional business. The company has maintained the strong EBITDA margins trajectory mainly driven by strong GPM performance. The...

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

10 Nov 2025

2054.80

-0.77%

Lupin (LPC IN) Q2FY26 Result Update Strong beat...

Buy: Lupin Ltd.

Prabhudas Lilladhar

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin Ltd.

09 Nov 2025, 12:00AM

2054.80

-0.77%

Strong quarter, grim outlook on pipeline

Hold: Lupin Ltd.

ICICI Securities Limited

Lupin delivered a beat of 9.5%/26.3%/21.8% in revenue/EBITDA/PAT vs our estimates in Q2FY26, driven by exclusive products like Tolvaptan and Mirabegron.